601 Identification of non-squamous NSCLC molecular subtypes and association with outcomes in the phase 3 IMpower150 study of 1L atezolizumab ± bevacizumab + carboplatin-paclitaxel in metastatic NSCLC

• Aditi Qamra,
• Hartmut Koeppen,
• Fabrice Barlesi,
• Federico Cappuzzo,
• Martin Reck,
• Mark A Socinski,
• Marcus Ballinger,
• Robert M Jotte,
• Barzin Nabet,
• Minu K Srivastava,
• Soren Muller,
• Tianshi Lu,
• Howard West,
• Habib Hamidi,
• Assaf Amitai,
• David S Shames

Affiliations

Aditi Qamra

9F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada

Hartmut Koeppen

1Genentech Inc., South San Francisco, CA, USA

Fabrice Barlesi

6Aix-Marseille University, Marseille, France

Federico Cappuzzo

5Istituto Nazionale Tumori ‘Regina Elena’, Rome, Italy

Martin Reck

3LungenClinic Grosshansdorf, Grosshansdorf, Germany

Mark A Socinski

2AdventHealth, Orlando, FL, USA

Marcus Ballinger

1Genentech Inc., South San Francisco, CA, USA

Robert M Jotte

8Rocky Mountain Cancer Center, Lone Tree, CO, USA

Barzin Nabet

1Genentech Inc., South San Francisco, CA, USA

Minu K Srivastava

1Genentech Inc., South San Francisco, CA, USA

Soren Muller

1Genentech Inc., South San Francisco, CA, USA

Tianshi Lu

1Genentech Inc., South San Francisco, CA, USA

Howard West

4City of Hope Cancer Center, Duarte, CA, USA

Habib Hamidi

1Genentech Inc., South San Francisco, CA, USA

Assaf Amitai

1Genentech Inc., South San Francisco, CA, USA

David S Shames

1Genentech Inc., South San Francisco, CA, USA